What good is a longer life if you have to spend half of it keeping up with the news? Ditch those endlessly scrolling feeds, and instead join us every ...
James Peyer: Why primary indications matter
“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs eve...
Evolution: Pulling doubled lifespan out of a hat
Part III of III in a series on the evolution of aging. (Part I, Part II) If all you had to go on was our genomes, you’d surely conclude that humans an...
The Hallmarks of Aging: Loss of Proteostasis
Part of a series on the Hallmarks of Aging. Proteins don’t do everything in your body, but it’s fair to say they control everything. What they don’t d...
Research roundup: The importance of energy in Alzheimer’s, and more
Since the world of Alzheimer’s therapeutics hasn’t seen much practical benefit from targeting harmful proteins like amyloid-beta, maybe ot...
FOXO vs. a harbinger of neurodegeneration
Long before the usual physiological signs, the withering of neurons and the gradual atrophy of the brain, that tip doctors off to the presence of a ne...
Research roundup: The Hippo in your heart, and more
The Hippo pathway controls cellular regeneration, so why not modify it to heal the heart after the scarring caused by a heart attack? Six weeks later,...
Media roundup: Pollution, priorities and press
If you live in the southwest United States or central Europe, you may be losing a year or more of your life to air pollution. Parts of China, India an...
Better together? Testing the first combination therapies for longevity
The normal mode of drug discovery is a pretty singular affair: one compound, one disease. This is enough for many traditional diseases, but when you’r...
Pet dogs on rapamycin are pictures of health
In the lab, rapamycin is a star geroprotector. In addition to boosting lifespan even when used in late life, it’s also been found specifically t...